Skip to main content
Equibles
VANI logo

VANI · Vivani Medical, Inc. · Metrics

Track VANI — free

Use VANI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VANI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.22 -0.01 (-0.81%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about our ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. ... Because these plans are not fully within our control and their successful execution cannot be considered certain, management has concluded that its plans do not alleviate the substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$111.85M
Shares
90.20M
Volume · Oct 5 95.18K Avg daily vol (3M) 456.47K

VANI metrics

54 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.23
Market cap
$111.85M

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
-9.2%
Price change (3M)
-2.4%
Price change (6M)
+13.9%
Price change (YTD)
+0.0%
Price change (1Y)
-19.6%
Trailing year
Price change (5Y)
—
52-week high
$1.87
52-week low
$0.94
Change from 52-week high
-34.2%
Change from 52-week low
+31.1%
Annualized volatility
67.9%
Annualized volatility (3M)
68.4%
Beta
1.4
RSI (14D)
43.4
Price vs SMA 50
-7.2%
Price vs SMA 200
-3.3%
Avg volume (3M)
456,472
Relative volume
0.2
Average dollar volume
$627,865

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
90.20M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.9
reciprocal yield 17.0%
FCF yield
-23.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-23.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-03-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$27.23M
Net income (TTM)
−$26.31M
Trailing 12 months
Diluted EPS (TTM)
$-0.35
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.21

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+47.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-138.7%
Return on assets
-63.2%
Debt / equity
—
Current ratio
3.2
EBITDA (TTM)
−$27.36M
Free cash flow (TTM)
−$26.50M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$19.89M
Total assets
$41.64M
Total debt
$2.20M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$25.30M
Capital expenditures (TTM)
$1.20M
R&D (TTM)
$18.00M
SG&A (TTM)
—
Stock compensation (TTM)
$1.37M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
39
13F filer change QoQ
-5
Institutional ownership
5.8%

Short interest

3 metrics
Short interest
0.8%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
$999,999
Insider-sentiment score
88 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1266806 CUSIP 92854B109 13F (30d) 1 filings 1 filers Visit website Investor relations